Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1792-1804

  Avilla, Elvira ^a   Guarino, Valentina ^a   Visciano, Carla ^a   Liotti, Federica ^a   Svelto, Maria ^a,c   Krishnamoorthy, GnanaPrakasam ^a   Franco, Renato ^c   Melillo, Rosa Marina ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GROWTH ARREST SPECIFIC PROTEIN 6; TYROSINE; TYROSINE KINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; THYROID CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THYROID NEOPLASMS; TRANSFECTION;

EID: 79952220537     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2186     Document Type: Article

References (50)

1. Rosai J. Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact. Endocr Pathol 2004;15: 293-6. (Pubitemid 40208908)
2. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004;15:319-27. (Pubitemid 40208912)
3. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;15;65:10199-207. (Pubitemid 41743711)
4. Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004;23:5958-67. (Pubitemid 39093540)
5. Melillo RM, Castellone MD, Guarino V, Falco VD, Cirafici AM, Salvatore G, et al. The RET/PTC-RAS-BRAF linear signalling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-108.
6. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, et al. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 2007;67:11821-9.
7. Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991;6:691-704.
8. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-31. (Pubitemid 21895263)
9. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin Kdependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006;273:5231-44.
10. Korshunov VA, Mohan AM, Georger MA, Berk BC. Axl, a receptor tyrosine kinase, mediates flow-induced vascular remodeling. Circ Res 2006;98:1446-52. (Pubitemid 43948070)
11. Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001;7:215-21. (Pubitemid 32148489)
12. Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses. J Thromb Haemost 2005;3:733-741. (Pubitemid 41647888)
13. Lemke and Rothlin. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-36.
14. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008;14:130-8. (Pubitemid 351377987)
15. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-9.
16. Inokuchi N, Zeki K, Morimoto I, Nakano Y, Fujihira T, Yamashita U, et al. Stimulatory effect of interleukin-1a on proliferation through a Ca2+/ calmodulin-dependent pathway of a human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res 1995;86:670-6.
17. Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, et al. Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastin thyroid carcinoma. J Clin Endoc Metab 2005;90:4703-09. (Pubitemid 41159361)
18. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. One and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987 Sep;7:3365-70.
19. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
20. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501.
21. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995;60:791-7.
22. Ito M, Nakashima M, Nakayama T, Ohtsuru A, Nagayama Y, Takamura N, et al. Expression of receptor-type tyrosine kinase, Axl, and its ligand, Gas6, in pediatric thyroid carcinomas around chernobyl. Thyroid 2002;12:971-5. (Pubitemid 35404131)
23. Zantek ND, Walker-Daniels J, Stewart J, Hansen RK, Robinson D, Miao H, et al. MCF-10A-NeoST: a new cell system for studying cell- ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001;7:3640-8. (Pubitemid 33070005)
24. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of axl in lung adenocarcinoma and correlation with tumour progression. Neoplasia 2005;7:1058-64.
25. Gustafsson A, Bostrom AK, Ljungberg B, Axelson H, Dahlbäck B. Gas6 and the receptor tyrosine kinase AXL in clear cell renal cell carcinoma. PLOS One 2009;4:1-10.
26. Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A, et al. Intracellular signalling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multisubstrate docking-site. Oncogene 1997;14:2619-31. (Pubitemid 27283101)
27. Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR. Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells. J Biol Chem 2008;283:16320-31.
28. Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994;84:1931-41. (Pubitemid 24286145)
29. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991;6:2113-20. (Pubitemid 21924053)
30. Ito T, Ito M, Naito S, Ohtsuru A, Nagayama Y, Kanematsu T, et al. Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 1999;9:563-7. (Pubitemid 29296118)
31. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, Andres AC. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 2001;12:819-24. (Pubitemid 32655092)
32. Sun W, Fujimoto J, Tamaya T. Coexpression of Gas6/ Axl in human ovarian cancers. Oncology 2004;66:450-7. (Pubitemid 39370236)
33. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204:36-44. (Pubitemid 40776804)
34. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002;8:361-67. (Pubitemid 34193951)
35. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 2002;22:1071-78. (Pubitemid 34836153)
36. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533-40. (Pubitemid 37174752)
37. Gjerdrum C, Tiron C, Hiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-9.
38. Alvarez H, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 2010;10:1009-18.
39. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2010 Oct 4. [Epub ahead of print].
40. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909-19.
41. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.
42. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8.
43. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28:3442-55.
44. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg- Kobligk H, et al. Dominant negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 2006;103:5799-804.
45. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene 2008;27:4044-55.
46. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905-15. (Pubitemid 351416577)
47. Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, et al. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood 2010;116:297-305.
48. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, et al. Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 2005;65:9294-303. (Pubitemid 41507996)
49. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70:1544-54.
50. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 2010;70:7570-9.